Frontlight ResearchEarly access
Fabry disease trials in Norway
1 of 2 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Taking peopleA Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
- Where
- Bergen
- Age
- 2 years to 17 years
- People
- 22 worldwide
- Run by
- Chiesi Farmaceutici S.p.A.
See details and how to joinNCT06328608 · EU 2022-503128-29-00